Andrew J Ahmann

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Current oral agents for type 2 diabetes. Many options, but which to choose when?
    Andrew J Ahmann
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University School of Medicine, 3181 SW Sam Jackson Park Rd, OP05, Portland, OR 97201 3098, USA
    Postgrad Med 111:32-4, 37-40, 43-6. 2002
  2. ncbi Designing and implementing insulin infusion protocols and order sets
    Andrew J Ahmann
    Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    J Hosp Med 3:42-54. 2008
  3. ncbi Guidelines and performance measures for diabetes
    Andrew J Ahmann
    Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 3098, USA
    Am J Manag Care 13:S41-6. 2007
  4. ncbi Lessons on developing a better basal insulin
    Andrew Ahmann
    Diabetes Center, Oregon Health and Science University, Portland, Oregon 97201, USA
    Diabetes Technol Ther 6:596-600. 2004
  5. ncbi Inpatient management of hospitalized patients with type 2 diabetes
    Andrew J Ahmann
    Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    Curr Diab Rep 4:346-51. 2004
  6. ncbi Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus
    Andrew Ahmann
    Oregon Health and Science University, 3181 SW Sam Jackson Prk Rd, OP05 DC, Portland, OR 97239, USA
    Am J Manag Care 17:S41-51. 2011
  7. ncbi Ultradian variation of blood glucose in intensive care unit patients receiving insulin infusions
    Stephen M Smith
    Pulmonary and Critical Care Medicine, Biomedical Research Building (UHN-67, 3181 SW Sam Jackson Park Rd, Oregon Health and Science University, Portland, OR 97239-3098, USA
    Diabetes Care 30:2503-5. 2007
  8. ncbi Reduction of hospital costs and length of stay by good control of blood glucose levels
    Andrew Ahmann
    Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
    Endocr Pract 10:53-6. 2004
  9. ncbi What to do when two oral agents fail to control type 2 diabetes--a matter of opinion or a matter of fact?
    Andrew J Ahmann
    Am J Med 116:276-8. 2004
  10. ncbi Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Diabetes Care 31:20-5. 2008

Detail Information

Publications11

  1. ncbi Current oral agents for type 2 diabetes. Many options, but which to choose when?
    Andrew J Ahmann
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University School of Medicine, 3181 SW Sam Jackson Park Rd, OP05, Portland, OR 97201 3098, USA
    Postgrad Med 111:32-4, 37-40, 43-6. 2002
    ..In this article, Drs Ahmann and Riddle provide an overview of the oral agents now available for the treatment of diabetes and discuss the clinical factors that help determine when to use which medication and what outcome to expect...
  2. ncbi Designing and implementing insulin infusion protocols and order sets
    Andrew J Ahmann
    Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    J Hosp Med 3:42-54. 2008
    ..In many cases, it is best to start more conservatively and methodically intensify the protocol. Continuous assessment of protocol errors, adverse events, staff satisfaction, and outcomes is vital to overall success...
  3. ncbi Guidelines and performance measures for diabetes
    Andrew J Ahmann
    Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 3098, USA
    Am J Manag Care 13:S41-6. 2007
    ....
  4. ncbi Lessons on developing a better basal insulin
    Andrew Ahmann
    Diabetes Center, Oregon Health and Science University, Portland, Oregon 97201, USA
    Diabetes Technol Ther 6:596-600. 2004
  5. ncbi Inpatient management of hospitalized patients with type 2 diabetes
    Andrew J Ahmann
    Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    Curr Diab Rep 4:346-51. 2004
    ..Inpatient subcutaneous insulin recommendations are general based on experience gained in the outpatient setting but offer a practical, physiologic approach...
  6. ncbi Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus
    Andrew Ahmann
    Oregon Health and Science University, 3181 SW Sam Jackson Prk Rd, OP05 DC, Portland, OR 97239, USA
    Am J Manag Care 17:S41-51. 2011
    ..CER is expected to open new avenues for research to clarify best practices in the treatment of T2DM, as well as possibly reduce treatment costs and improve the overall quality of public health...
  7. ncbi Ultradian variation of blood glucose in intensive care unit patients receiving insulin infusions
    Stephen M Smith
    Pulmonary and Critical Care Medicine, Biomedical Research Building (UHN-67, 3181 SW Sam Jackson Park Rd, Oregon Health and Science University, Portland, OR 97239-3098, USA
    Diabetes Care 30:2503-5. 2007
  8. ncbi Reduction of hospital costs and length of stay by good control of blood glucose levels
    Andrew Ahmann
    Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
    Endocr Pract 10:53-6. 2004
    ..Comprehensive analyses of cost-effectiveness through prospective, randomized intervention trials are needed, however, to characterize these benefits more precisely...
  9. ncbi What to do when two oral agents fail to control type 2 diabetes--a matter of opinion or a matter of fact?
    Andrew J Ahmann
    Am J Med 116:276-8. 2004
  10. ncbi Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Diabetes Care 31:20-5. 2008
    ....
  11. ncbi The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes
    Thomas J Hoerger
    Research Triangle Institute International, USA
    J Manag Care Pharm 14:S2-14; quiz 15-6. 2008
    ....